SAFETY OF COMBINED INJECTION OF VACCINES AGAINST HIB-INFECTION (the data on pilot project fulfilled in Murmansk region and Yaroslavl)
Abstract
Key words: children, hemophilic infection, vaccination, post-vaccinal period, safety.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(6):36-41)
About the Authors
S.M. KharitRussian Federation
V.Yu. Rodnikova
Russian Federation
T.A. Druzhinina
Russian Federation
E.Ya. Frolova
Russian Federation
O.K. Mamontova
Russian Federation
References
1. Общий протокол для наблюдения за Haemophilus influenzae типа b среди населения. www.who.int/vaccines-documents/DocsPDF/www9723.pdf. Geneva: World Health Organization. 1995.
2. EU–IBIS Network. Invasive Haemophilus influenzae in Europe 2006. Доступно на: www.euibis.org. Health Protection Agency. 2006.
3. Cripps A.W., Otczyk D.C., Kyd J.M. Bacterial otitis media: a vaccine preventable disease? Vaccine. 2005; 23: 2304-2310.
4. Kofteridis D., Samonis G., Mantadakis E. et al. Lower respiratory tract infections caused by Haemophilus influenzae: clinical features and predictors of outcome. Med. Sci. Monit. 2009; 15: 135–139.
5. Rudan I., Tomaskovic L., Boschi-Pinto C., Campbell H. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull. World Health Organ. 2004; 82: 895–903.
6. Moxon E.R. Bacterial variation, virulence and vaccines. Microbiology. 2009; 155: 997–1003.
7. Ceyhan M., Yildirim I., Balmer P. et al. A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg. Infect. Dis. 2008; 14: 1089–1096.
8. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin. Microbiol. Rev. 2000; 13: 302–317.
9. Gessner B.D., Sutanto A., Linehan M. et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet randomised vaccine probe trial. Lancet. 2005; 365: 43-52.
10. Mulholland K., Hilton S., Adegbola R. et al. Randomised trial of Haemophilus influenzae type b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet. 1997; 349: 1191–1197.
11. Morris S.K., Moss W.J., Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect. Dis. 2008; 8: 435–443.
12. Kilpi T.M., Silfverdal S.A., Nilsson L. et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum. Vaccin. 2009; 5: 18–25.
13. Halperin S.A., Tapiero B., Diaz-Mitoma F. et al. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12–14 months of age. Vaccine. 2009; 27: 2540–2547.
14. Progress toward introduction of Haemophilus influenzae type b vaccine in low-income countries worldwide, 2004-2007. MMWR Morb. Mortal. Wkly. Rep. 2008; 57: 148–151.
15. Guerra F.A., Blatter M.M., Greenberg D.P. et al. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics. 2009; 123: 301–312.
16. Sharma H.J., Multani A.S., Dutta A.K. et al. Safety and immunogenicity of an indigenously developed Haemophilus influenzae type b conjugate vaccine through various phases of clinical trials. Vaccinе. 2009; 5: 483–487.
17. Makela P.H., Kayhty H., Leino T. et al. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine. 2003; 22: 287–292.
18. WHO vaccine-preventable diseases: monitoring system. 2007 global summary. Geneva: World Health Organization. 2007.
19. Rossi I.A., Zuber P.L., Dumolard L. et al. Introduction of Hib vaccine into national immunization programmes: a descriptive analysis of global trends. Vaccine. 2007; 25: 7075–7080.
20. Griffiths U.K., Miners A. Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature. Expert. Rev. Pharmacoecon. Outcomes. Res. 2009; 9: 333–346.
21. Ribeiro G.S., Lima J.B., Reis J.N. et al. Haemophilus influenzae meningitis 5 years after introduction of the Haemophilus influenzae type b conjugate vaccine in Brazil. Vaccine. 2007; 25: 4420–4428.
22. Mendsaikhan J., Watt J.P., Mansoor O. et al. Childhood bacterial meningitis in Ulaanbaatar, Mongolia, 2002-2004. Clin. Infect. Dis. 2009; 48 (Suppl. 2): 141–146.
23. Королева И.С., Демина А.А., Платонов А.Е. и др. Эпидемиологический надзор за гнойными бактериальными менингитами: материалы 20–летних наблюдений. Эпидемиология и вакцинопрофилактика. 2003; 5: 10–13.
24. Платонов А.Е., Николаев М.К. Заболеваемость гнойными менингитами у детей в возрасте до 5 лет в регионах России. Эпидемиология и инфекционные болезни. 2007; 3: 10–18.
25. Николаев М.К., Платонов А.Е. Инфекция, вызываемая Haemophilus influenzae серотипа b (Hib), и перспективы её вакцинопрофилактики в России. Эпидемиология и инфекционные болезни. 2009; 4: 125–133.
Review
For citations:
Kharit S., Rodnikova V., Druzhinina T., Frolova E., Mamontova O. SAFETY OF COMBINED INJECTION OF VACCINES AGAINST HIB-INFECTION (the data on pilot project fulfilled in Murmansk region and Yaroslavl). Current Pediatrics. 2009;8(6):36-41.
Email this article 
